Navigation Links
Voices Against Brain Cancer Comments on Discovery of Nano Drug That May Aid in Treatment of Brain Tumors
Date:7/19/2013

New York, NY (PRWEB) July 19, 2013

On July 19, Voices Against Brain Cancer, an organization dedicated to brain cancer research and advocacy, comments on the discovery of a Nano drug, SapC-DOPS, that may aid in treating brain tumors.

According to a July 17, 2013 article published on MedicalXpress.com entitled “Nano drug crosses blood-brain tumor barrier, targets brain tumor cells and blood vessels,” a recent animal and laboratory study conducted by researchers at the Ohio State University Comprehensive Cancer Center, Arthur G. James Cancer Hospital and the Richard J. Solove Research Institute, showed that an “experimental drug in early development for aggressive brain tumors can cross the blood-brain tumor barrier and kill tumor cells and block the growth of tumor blood vessels.” These findings support further development of the drug as a “novel treatment for brain tumors.”

With 3,470 new brain tumor cases in the United States expected this year and a median survival rate of about 15 months, glioblastoma multiforme is the most common and aggressive form of brain cancer. One of the major obstacles obstructing effective treatment of this disease is the blood-brain barrier which is the tight fit of cells that make up the blood vessels in the brain. It protects the brain from toxins in the blood but also keeps drugs in the bloodstream from reaching the brain tumors.

“Few drugs have the capacity to cross the tumor blood-brain barrier and specifically target tumor cells,” says principal investigator on the study, Balveen Kaur, PhD and associate professor of neurological surgery and chief of the Dardinger Laboratory of Neurosciences at the OSUCCC-James. “Our preclinical study indicates that SapC-DOPS does both and inhibits the growth of new tumor blood vessels, suggesting that this agent could one day be an important treatment for glioblastoma and other solid tumors.”

Michael Klipper, Chairman of Voices Against Brain Cancer, an organization dedicated to brain cancer research and advocacy, comments on the recent discovery. “Every single day, we hear of new scientific discoveries being made for brain cancer treatment. It gives us and the rest of the brain cancer community hope that one day this horrible disease will be cured. Hats off to Dr. Kaur and his team for their continuous efforts.”

VABC has a wide variety of initiatives in place for brain cancer research, awareness and support. The organization’s research grants fund cutting-edge research programs that will have a monumental impact on the diagnosis and treatment of brain cancer. VABC currently funds research at several esteemed institutions such as Brookhaven National Laboratory, Cleveland Clinic, Columbia, Cornell, Duke, Harvard, John Hopkins, Memorial Sloan-Kettering and Yale, to name a few.

VABC's mission is to find a cure for brain cancer by advancing scientific research, increasing awareness within the medical community and supporting patients, their families and caregivers afflicted with this devastating disease.

For press inquiries, please contact: 5W Public Relations
###

Read the full story at http://www.prweb.com/releases/2013/7/prweb10942215.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. Voices Against Brain Cancer Commends Neuropsychologist and Team for Research on Cognitive Brain-Training for Cancer Survivors
2. Voices Against Brain Cancer Comments on Discovery of a Cause of Resistance to Therapy in Cases of Brain Cancer
3. Voices Against Brain Cancer Comments on Recent Discovery in Ongoing Brain Cancer Research
4. Voices Against Brain Cancer Awards Grant to Tocagen to Support Investigation of Toca 511 & Toca FC in Patients with Recurrent Brain Cancer
5. Voices Against Brain Cancer Commends Family For Remaining Positive Despite Three Cancer Diagnoses
6. Voices Against Brain Cancer Commends Father of Nine for Running Marathons Despite Diagnosis
7. Voices Against Brain Cancer Commends Brain Cancer Survivor For His Positive Outlook
8. Voices Against Brain Cancer Comments on New Discovery Made by Researchers in Regards to the Tie between Brain Cancer and Genetics
9. Voices Against Brain Cancer Comments on New Potential Development in Brain Cancer Treatment
10. Voices Against Brain Cancer Commends Family for their Ongoing Efforts to Spread Brain Cancer Awareness
11. Avatar therapy helps silence voices in schizophrenia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/25/2017)... ... 25, 2017 , ... Somnoware, a leading provider of digital ... module. Using this new feature, sleep physicians can now predict the likelihood of ... airway pressure (CPAP), oral, or other forms of sleep apnea therapy. The Somnoware ...
(Date:4/25/2017)... ... April 25, 2017 , ... ... healthcare products, is introducing Flexadin UCII, part of the EQUISTRO line, at this ... joint health in horses at the immunologic level. , The scientifically-developed Flexadin UCII ...
(Date:4/24/2017)... (PRWEB) , ... April 24, 2017 , ... ... technology yesterday, featuring Bring Your Own Device (BYOD) capabilities at Telehealth 2.0, the ... CNS’ pre-packaged telehealth bundles, which pairs medical devices with a pre-programmed tablet in ...
(Date:4/24/2017)... Salt Lake City, UT (PRWEB) , ... April 24, 2017 , ... ... in their efforts to encourage sustainability, innovate new strategies to reduce waste, and support ... all-natural herbal remedy provider. They look to nature to find solutions for health issues, ...
(Date:4/24/2017)... ... April 24, 2017 , ... The bar for just about everything—apparel, eyewear, ... the rarified air of pop and film stardom.(1) Not to be left out is ... smile. Grins now run the gamut from being encrusted with jewels and precious metals ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... April 20, 2017  Cogentix Medical, Inc. (NASDAQ: ... providing the Urology, Uro/Gyn and Gynecology markets with ... Keswani has joined the Company as Senior Vice ... created position, Mr. Keswani will report directly to ... "Our organization is delighted that Ash has ...
(Date:4/20/2017)... Mass. , April 20, 2017  RXi ... developing innovative therapeutics that address significant unmet medical ... data from the Company,s consumer product development program, ... at the Society for Investigative Dermatology (SID) 76 ... to advance and promote the sciences relevant to ...
(Date:4/20/2017)... April 20, 2017  AbbVie (NYSE: ABBV), a ... (n=145/146) of chronic hepatitis C virus (HCV) infected ... 6 and compensated cirrhosis (Child-Pugh A) achieved sustained ... ) with its investigational, pan-genotypic regimen of glecaprevir/pibrentasvir ... seen following 12 weeks of G/P treatment without ...
Breaking Medicine Technology: